Loading clinical trials...
Loading clinical trials...
A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant
Conditions
Interventions
A/H7N9
MF59
+1 more
Locations
7
United States
University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic
Birmingham, Alabama, United States
Saint Louis University - Center for Vaccine Development
St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center - Infectious Diseases
Cincinnati, Ohio, United States
Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC)
Nashville, Tennessee, United States
The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)
Galveston, Texas, United States
Baylor College of Medicine - Molecular Virology and Microbiology
Houston, Texas, United States
Start Date
November 2, 2018
Primary Completion Date
April 30, 2020
Completion Date
April 30, 2020
Last Updated
May 17, 2021
NCT07240558
NCT02839330
NCT02485639
NCT03553940
NCT03328325
NCT03318315
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions